Lancet Neurology

Article	Citations
The East Asian Parkinson Disease Genomics Consortium	4636
Implications of the KIWE trial for low-income and lower-middle-income countries	689
Multidisciplinary care for amyotrophic lateral sclerosis	688
Dementia diagnosis in the anti-amyloid era	636
Continuous subcutaneous levodopa–carbidopa infusion for Parkinson's disease	626
Treatment-induced neuropathy of diabetes: an underdiagnosed entity – Authors' reply	486
Correction to Lancet Neurol 2024; 23: 168–77	478
Correction to Lancet Neurol 2022; 21: 42–52	426
Correction to Lancet Neurol 2021; 20: 448–59	401
Lessons and future directions for GBA1-targeting therapies	400
The predictive value and clinical use of the neurological pupillary index – Authors' reply	391
Safety and efficacy of early versus delayed acetylsalicylic acid after surgery for spontaneous intracerebral haemorrhage in China (E-start): a prospective, multicentre, open-label, blinded-endpoint, r	390
New therapies for Pompe disease: are we closer to a cure?	368
RAB32 mutation in Parkinson's disease	362
Clinical descriptors of disease trajectories in patients with traumatic brain injury in the intensive care unit (CENTER-TBI): a multicentre observational cohort study	308
Pseudomedicine for sports concussions in the USA	297
Bailout intracranial angioplasty or stenting following thrombectomy for acute large vessel occlusion in China (ANGEL-REBOOT): a multicentre, open-label, blinded-endpoint, randomised controlled trial	293
Safety and efficacy of erythropoietin for the treatment of patients with optic neuritis (TONE): a randomised, double-blind, multicentre, placebo-controlled study	285
Variant-dependent heterogeneity in amyloid β burden in autosomal dominant Alzheimer's disease: cross-sectional and longitudinal analyses of an observational study	279
Safety and efficacy of losartan for the reduction of brain atrophy in clinically diagnosed Alzheimer's disease (the RADAR trial): a double-blind, randomised, placebo-controlled, phase 2 trial	271
The relevance of social and commercial determinants for neurological health	268
Global burden of stroke: dynamic estimates to inform action	265
Safety and efficacy of lower-sodium oxybate in adults with idiopathic hypersomnia: a phase 3, placebo-controlled, double-blind, randomised withdrawal study	255
Comparison of amyloid burden in individuals with Down syndrome versus autosomal dominant Alzheimer's disease: a cross-sectional study	242
Traumatic brain injury research: homogenising heterogeneity	240

A biological classification of Huntington's disease: the Integrated Staging System	224
Increasing diversity in dementia research	210
Management of atherosclerotic extracranial carotid artery stenosis	202
Anti-CD19 CAR T cells for refractory myasthenia gravis	201
A chilly tale of dementia	200
Trials in intracerebral haemorrhage: a path to success?	194
A study in healing the wounds of trauma	188
Epilepsy syndromes: an essential piece of the puzzle	186
Beyond the modular brain	180
Elia M Pestana Knight	178
Delving into the human mind	174
Albert Kwaku Akpalu	173
A blood test for Alzheimer's disease: a step forward	158
Safe laboratory management of prions and proteopathic seeds	154
Considering the neurological health needs of LGBTQIA people	154
Diana Cejas	153
The Genetic Epidemiology of Parkinson's Disease view – Authors' reply	151
From stroke awareness to stroke action awareness	149
Gene therapy for X-linked myotubular myopathy: the challenges	148
The prescription of valproate: risk of harm	141
Comparative effectiveness of cognitive behavioural therapy, modafinil, and their combination for treating fatigue in multiple sclerosis (COMBO-MS): a randomised, statistician-blinded, parallel-arm tri	139
Correction to Lancet Neurol 2022; 21: 284–94	138
Amyotrophic lateral sclerosis from genotoxins alone?	137
Correction to Lancet Neurol 2023; 22: 812–25	137
A nasal CGRP receptor antagonist for acute migraine therapy	132
Surrogate endpoints for progressive multifocal leukoencephalopathy	131
Complex regional pain syndrome: advances in epidemiology, pathophysiology, diagnosis, and treatment	131
Parkinson's disease is a recognisable and useful diagnostic entity	129
Development of treatments for Down syndrome	125
Aspiring to restore arm and hand function after stroke	121
Long-term safety, tolerability, and efficacy of eptinezumab in chronic cluster headache (CHRONICLE): an open-label safety trial	119
A sensitive portrayal of a controversial condition	118
Movement disorders research in 2021: cracking the paradigm	112
Intracranial pressure monitoring with and without brain tissue oxygen pressure monitoring for severe traumatic brain injury in France (OXY-TC): an open-label, randomised controlled superiority trial	111
Fluid balance and outcome in critically ill patients with traumatic brain injury (CENTER-TBI and OzENTER-TBI): a prospective, multicentre, comparative effectiveness study	111
Safety and efficacy of rituximab versus dimethyl fumarate in patients with relapsing-remitting multiple sclerosis or clinically isolated syndrome in Sweden: a rater-blinded, phase 3, randomised contro	109
B cell-targeting chimeric antigen receptor T cells as an emerging therapy in neuroimmunological diseases	108
Encephalitis awareness: our ambitious global endeavour	106
Better buildings for elderly people to thrive	102
Poldi Wilbrink	100
New results for risdiplam in spinal muscular atrophy	99
Expansion of stenting indications in the USA	97
Correction to Lancet Neurol 2021; 20: 687–89	96
Neurological infections in 2023: surveillance and prevention	96
Effect of blood pressure-lowering agents on microvascular function in people with small vessel diseases (TREAT-SVDs): a multicentre, open-label, randomised, crossover trial	95
Jessica Ailani	95
Responsible innovation in neurology	94
The International Brain Initiative: enabling collaborative science	93
Multiple sclerosis in 2022: old players, new insights	92
Brain health in the Philippines	92

Correction to Lancet Neurol 2024; 23: 110–22	91
Correction to Lancet Neurol 2022; 21: 620–31	91
Detection of ionising radiation by the CNS: a case report	89
Riluzole and spinocerebellar ataxia type 2: the ATRIL trial	87
Redefining use of MRI for patients with multiple sclerosis	87
Cognitive function in people with functional seizures	86
The ATTeST trial in ataxia telangiectasia: some concerns – Authors' response	85
A health literacy campaign for Parkinson's disease in Africa: a novel campaign to break down language barriers	83
Changing multiple-sclerosis-induced thoughts and behaviours	82
Supporting young carers across neurological disorders	81
Learning to be an adult with a disability	80
A proposal for equity neuroscience	79
Major advances in Parkinson's disease over the past two decades and future research directions	79
Indobufen versus aspirin in patients with acute ischaemic stroke in China (INSURE): a randomised, double-blind, double-dummy, active control, non-inferiority trial	78
α-synuclein seed amplification and its uses in Parkinson's disease	78
Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial	76
Safety and efficacy of intra-erythrocyte dexamethasone sodium phosphate in children with ataxia telangiectasia (ATTeST): a multicentre, randomised, double-blind, placebo-controlled phase 3 trial	76
Comparative effectiveness of azathioprine and mycophenolate mofetil for myasthenia gravis (PROMISE-MG): a prospective cohort study	76
Spontaneous intracranial hypotension: searching for the CSF leak	75
A new characterisation of acute traumatic brain injury: the NIH-NINDS TBI Classification and Nomenclature Initiative	74
Bastiaan Bloem: power against Parkinson's disease	74
Sleeping matters	73
Living with dementia: seeing the world and adapting to it	71
Eugenia Martínez	71
Brains are neither pink nor blue but fifty shades of grey matter	71
Headache research in 2023: advancing therapy and technology	71
Correction to Lancet Neurol 2024; 23: 961–62	70
Blocking inhibitors of axon growth after spinal cord injury	70
Monitoring brainwaves while gallery visitors view artworks	69
ELEVATEd hope for patients after migraine treatment failure	68
Pragmatic solutions for the global burden of stroke	66
Highlights in traumatic brain injury research in 2024	65
Andrea Schneider	64
Detection of awareness after brain injury: time for change	64
Improving thrombolysis efficiency for acute ischaemic stroke	64
Epilepsy research in 2022: clinical advances	64
A call for optimal oral care in patients with ALS	64
Neuroprotection in acute ischaemic stroke: reasons for optimism?	62
Expanding the spectrum of type 1 IFN neuroinflammation	61
Thrombolysis before endovascular treatment of tandem lesions	60
Consciousness contextualised	60
Safety and efficacy of tamoxifen in boys with Duchenne muscular dystrophy (TAMDMD): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial	58
Correction to Lancet Neurol 2024; 23: 344–81	57
Targeting auto-antibodies for CIDP: hope and questions	57
Safety, tolerability, and efficacy of fasudil in amyotrophic lateral sclerosis (ROCK-ALS): a phase 2, randomised, double-blind, placebo-controlled trial	57
Your After-Visit Summary—May 29, 2042	57
Effect of atherosclerosis on 5-year risk of major vascular events in patients with transient ischaemic attack or minor ischaemic stroke: an international prospective cohort study	56
The AfrAbia+plus Parkinson's Disease Genomic Consortium	56
Whole genome sequencing for the diagnosis of neurological repeat expansion disorders in the UK: a retrospective diagnostic accuracy and prospective clinical validation study	56
Siddharth Srivastava	55
The global challenge of hypertension	55
Safety and efficacy of occipital nerve stimulation for attack prevention in medically intractable chronic cluster headache (ICON): a randomised, double-blind, multicentre, phase 3, electrical dose-con	55
Safety, tolerability, and efficacy of subcutaneous efgartigimod in patients with chronic inflammatory demyelinating polyradiculoneuropathy (ADHERE): a multicentre, randomised-withdrawal, double-blind,	54
Safety and efficacy of cipaglucosidase alfa plus miglustat versus alglucosidase alfa plus placebo in late-onset Pompe disease (PROPEL): an international, randomised, double-blind, parallel-group, phas	53
Safety and efficacy of ganaxolone in patients with CDKL5 deficiency disorder: results from the double-blind phase of a randomised, placebo-controlled, phase 3 trial	52
Diagnosis and treatment of orthostatic hypotension	52
Advances and controversies in frontotemporal dementia: diagnosis, biomarkers, and therapeutic considerations	52
Clinical trials for progressive multiple sclerosis: progress, new lessons learned, and remaining challenges	52
The torment of needing to know for sure	51
Blood-based biomarkers for Alzheimer's disease: towards clinical implementation	51
The cultural history of dementia	50
Geoffrey Manley: TBI guy	49
Biomedical research must change as the climate does	49
Charles Sherrington's apparatus	49
The bases of remembrance	48
Neurosurgical lesioning for Tourette syndrome – Authors' reply	47
Thank you to The Lancet Neurology's peer reviewers in 2023	47
Major advances in sleep neurology: 2002–22	47
Laquinimod, Huntington's disease, and disease modification	45
A brain design for life	45
Carlayne Jackson: leading the American Academy of Neurology	45
Early atrial fibrillation rhythm control after stroke	45
Sleep research in 2023: beyond the bare necessities	44
Platelet glycoprotein VI inhibition: a promising therapeutic avenue in acute ischaemic stroke	44
Angela Dos Santos	40
A decisive year for the neurological community	38
Changing the landscape of neurological education	38
Tenecteplase versus alteplase for early treatment of ischaemic stroke – Authors' reply	38
Correction to Lancet Neurol 2024; 23: 465–76	37
Further support for rituximab in relapsing multiple sclerosis	37

Correction to Lancet Neurol 2021; 20: 1012–16	37
Advances in amyotrophic lateral sclerosis research in 2022	37
Therapies for myasthenia gravis: FcRn inhibition and beyond	37
Differential diagnosis and comparison of diagnostic algorithms in children and adolescents with autoimmune encephalitis in Spain: a prospective cohort study and retrospective analysis	36
Tenecteplase versus alteplase in stroke thrombolysis: the last piece of the puzzle?	36
No area of stroke research should be left behind	36
Challenging the management of blood pressure before intravenous thrombolysis in acute ischaemic stroke	36
The four most common genetic subtypes of amyotrophic lateral sclerosis: state of the art and future directions	35
NfL is ready for translation into paediatrics	35
Frailty and outcome after traumatic brain injury	35
Advances and ongoing research in the treatment of autoimmune neuromuscular junction disorders	34
Digital mobility measures to predict Parkinson's disease	33
The complex pathway between amyloid β and cognition: implications for therapy	33
Safety and efficacy of trehalose in amyotrophic lateral sclerosis (HEALEY ALS Platform Trial): an adaptive, phase 2/3, double-blind, randomised, placebo-controlled trial	33
Safety and efficacy of avalglucosidase alfa versus alglucosidase alfa in patients with late-onset Pompe disease (COMET): a phase 3, randomised, multicentre trial	33
Improving epilepsy diagnosis across the lifespan: approaches and innovations	32
The Boston criteria version 2.0 for cerebral amyloid angiopathy: a multicentre, retrospective, MRI–neuropathology diagnostic accuracy study	31
Teshamae Monteith	31
Stimulation of TREM2 with agonistic antibodies—an emerging therapeutic option for Alzheimer's disease	31
For a dementia diagnosis, clinical acumen must precede biomarkers	31
Helping to bring the crisis home	30
Correction to Lancet Neurol 2021; 20: 615–26	30
Correction to Lancet Neurol 2021; 20: 739–52	30
Sleep matters in anti-LGI1 encephalitis	30
Globally advancing neurological education in headache	30
Correction to Lancet Neurol 2023; 22: 209–17	30
Revisiting levodopa for advanced Parkinson's disease	29
Friston's theory of everything	29
Nitrous oxide and its neurological harms	29
Neuroscience research in 2024: advances in blood biomarkers and brain omics	28
Maria Trojano: advocate for real-world multiple sclerosis studies	28
Global burden of meningitis and implications for strategy	27
Nanna Brix Finnerup: integrity and openness to alternatives	27
Correction to Lancet Neurol 2024; 23: 344–81	26
Clinical characterisation of patients in the post-acute stage of anti-NMDA receptor encephalitis: a prospective cohort study and comparison with patients with schizophrenia spectrum disorders	26
Heart health meets cognitive health: evidence on the role of blood pressure	26
Blue as an orange	26
Off-label use of aducanumab for cerebral amyloid angiopathy	26
Cognitive and psychiatric features of anti-NMDA receptor encephalitis	26
Abandon the NAC in α-synuclein	25
Time to get serious about the Global Action Plan on dementia	25
RAB32 mutation in Parkinson's disease	25
The prescription of valproate: risk of harm	25
Emerging insights into the complex genetics and pathophysiology of amyotrophic lateral sclerosis	24
Apixaban versus aspirin for stroke prevention in people with subclinical atrial fibrillation and a history of stroke or transient ischaemic attack: subgroup analysis of the ARTESiA randomised controll	24
Safety and efficacy of givinostat in boys with Duchenne muscular dystrophy (EPIDYS): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial	24
Correction to Lancet Neurol 2018; 17: 954–76	24
Advances in diagnosis, classification, and management of pain in Parkinson's disease	24
2021 MAGNIMS–CMSC–NAIMS consensus recommendations on the use of MRI in patients with multiple sclerosis	24
Neuroscience in the 21st century: circuits, computation, and behaviour	24
Global, regional, and national burden of disorders affecting the nervous system, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021	24
Treatment of acute subdural haematoma – Authors' reply	23
CGRP-targeted drugs for migraine: still many uncertainties	23
Lightning progress in child neurology in the past 20 years	23
Amyotrophic lateral sclerosis: a lesson in translation	23
Dancing with paper	23
Vittorio Marchi's staining	22
With thanks to our peer reviewers in 2022	22
Cerebral amyloid angiopathy criteria: the next generation	21
The hidden unity of the mind	21
Treatment of asymptomatic carotid stenosis in SPACE-2	21
Anticoagulation in people with atrial fibrillation after intracranial haemorrhage	21
Addressing neurological burden in the Americas	21
Innovation in the prevention of neurological diseases	21
Transforming amyotrophic lateral sclerosis into a liveable disease	20
Prehospital screening of acute stroke with the National Institutes of Health Stroke Scale (ParaNASPP): a stepped-wedge, cluster-randomised controlled trial	19
Differential diagnosis of suspected multiple sclerosis: global health considerations	19
A disease-specific therapy in facioscapulohumeral muscular dystrophy	19
Correction to Lancet Neurol 2021; 20: 703–04	19
Prioritising faster, individualised rescue treatment in status epilepticus – Authors' reply	19
A neurotransmitter with a fascinating story	19
Fetal exposure to antiseizure medications: reassurance and concerns	19
A biobank for Parkinson's disease and atypical parkinsonism in central Asian and Transcaucasian regions	18
Carotid revascularisation for carotid stenosis	18
Chronic effects of inflammation on tauopathies	18
Time to end the stigma of epilepsy	18
CGRP blockade and cluster headache: another step forward	18
Risk of new disease activity in patients with multiple sclerosis who continue or discontinue disease-modifying therapies (DISCOMS): a multicentre, randomised, single-blind, phase 4, non-inferiority tr	18
Neurology cannot be embedded in non-communicable disease agendas	18
Carpal tunnel syndrome: updated evidence and new questions	17
The neuropsychiatry of Parkinson's disease: advances and challenges	17
Turin as a neuroscience cradle	17
Apixaban versus no anticoagulation after anticoagulation-associated intracerebral haemorrhage in patients with atrial fibrillation in the Netherlands (APACHE-AF): a randomised, open-label, phase 2 tri	17
A genetic basis for the severity of multiple sclerosis	17
Incremental prognostic value of acute serum biomarkers for functional outcome after traumatic brain injury (CENTER-TBI): an observational cohort study	17
Antibiotic neuromuscular junction myasthenic mimetics	17
Targeting C9orf72 in people with ALS	16
A deep scream into the future	16
Alzheimer's disease: a history revisited	16
Cerebral cavernous malformations: to operate or not?	16
Kathleen Friel	16
Multiple sclerosis meets systems immunology	16
Rigmor Højland Jensen: the headache warrior	15
Expression of concern—Serotonergic pathology and disease burden in the premotor and motor phase of A53T α-synuclein parkinsonism: a cross-sectional study	15
Changing views of disability	15